ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S.

The other skin changes in the healing sites were slight erythema (1), hyperpigmentation (2) and hypopigmentation (1). The pre- and post-treatment sizes of the lesions and overall clinical ...

Sensus Healthcare (SRTS – Research Report) received a Buy rating and a $18.00 price target from Lake Street analyst Ben Haynor today. The ...

Offering image-guided superficial radiation therapy to rural populations could mend health disparities in nonmelanoma skin cancer treatment, according to a study published in Cancers. Historically ...

Objective: Intralesional injections of interferon have been reported to provide successful results in the treatment of basal cell carcinoma. However, there are only a few reports describing the ...

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- For patients with nodular basal cell carcinoma (nBCC), it cannot be concluded that superficial curettage (SC) plus imiquimod cream, 5 percent, is ...

Gentle Cure is the brand name for an image-guided superficial ionizing radiation therapy (IG-SRT). It’s a nonsurgical treatment option for basal and squamous cell skin cancers. Gentle Cure uses ...

Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as the face. Locally advanced tumors in particular can be difficult to treat surgically. A ...